Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study
Sign Up to like & getrecommendations! Published in 2018 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2018.1513793
Abstract: ABSTRACT Background: The challenges of managing relapsed ovarian cancer increase as more advanced lines of chemotherapy are achieved. Methods: A case study is presented to illustrate the complexities of selecting treatment in a patient with… read more here.
Keywords: platinum; relapsed ovarian; treatment; ovarian cancer ... See more keywords
297 Bevacizumab in relapsed ovarian cancer: an indian tertiary care canter experience
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-igcs.297
Abstract: Objectives Bevacizumab, an anti-vascular endothelial growth factor antibody with chemotherapy improved the progression-free survival (PFS) in relapsed ovarian cancer. There is a paucity of data regarding the use of bevacizumab from the Indian subcontinent. Methods… read more here.
Keywords: ovarian cancer; free survival; cancer; relapsed ovarian ... See more keywords
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.19.02745
Abstract: PURPOSE A phase II study (ClinicalTrials.gov identifier: NCT00628251) showed activity of olaparib capsules versus pegylated liposomal doxorubicin in patients with germline BRCA-mutated platinum-resistant or partially platinum-sensitive relapsed ovarian cancer. We conducted a phase III trial… read more here.
Keywords: chemotherapy; sensitive relapsed; ovarian cancer; chemotherapy patients ... See more keywords
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.6002
Abstract: 6002Background: SOLO2 (ENGOT ov-21; NCT01874353) showed that maintenance therapy with the PARP inhibitor olaparib in pts with platinum-sensitive relapsed ovarian cancer (PSROC) and a BRCA mutation ... read more here.
Keywords: pts platinum; relapsed ovarian; sensitive relapsed; ovarian cancer ... See more keywords